On March 29, 2023,
UBS
initiated coverage of DexCom with
a Buy recommendation.
Analyst Price Forecast Suggests 18.96% Upside
As of March 28, 2023,
the average one-year price target for DexCom is $135.40.
The forecasts range from a low of $111.10 to a high of $157.50.
The average price target represents an increase of 18.96% from its latest reported closing price of $113.82.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for DexCom
is $3,546MM, an increase of 21.86%.
The projected annual non-GAAP EPS
is $1.10.
What are Large Shareholders Doing?
Baillie Gifford &
holds 17,303K shares
representing 4.48% ownership of the company.
In it’s prior filing, the firm reported owning 18,105K shares, representing
a decrease
of 4.64%.
The firm
decreased
its portfolio allocation in DXCM by 47.75% over the last quarter.
Sands Capital Management
holds 15,514K shares
representing 4.01% ownership of the company.
In it’s prior filing, the firm reported owning 16,693K shares, representing
a decrease
of 7.60%.
The firm
increased
its portfolio allocation in DXCM by 31.54% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 11,746K shares
representing 3.04% ownership of the company.
In it’s prior filing, the firm reported owning 11,715K shares, representing
an increase
of 0.26%.
The firm
increased
its portfolio allocation in DXCM by 30.18% over the last quarter.
Jpmorgan Chase &
holds 10,647K shares
representing 2.76% ownership of the company.
In it’s prior filing, the firm reported owning 10,248K shares, representing
an increase
of 3.75%.
The firm
increased
its portfolio allocation in DXCM by 34.10% over the last quarter.
Capital Research Global Investors
holds 9,462K shares
representing 2.45% ownership of the company.
In it’s prior filing, the firm reported owning 10,530K shares, representing
a decrease
of 11.30%.
The firm
increased
its portfolio allocation in DXCM by 16.21% over the last quarter.
What is the Fund Sentiment?
There are 1891 funds or institutions reporting positions in DexCom.
This is an increase
of
134
owner(s) or 7.63% in the last quarter.
Average portfolio weight of all funds dedicated to DXCM is 0.47%,
an increase
of 17.12%.
Total shares owned by institutions increased
in the last three months by 0.56% to 443,061K shares.
The put/call ratio of DXCM is 1.18, indicating a
bearish
outlook.
Dexcom Background Information
(This description is provided by the company.)
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
